LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Pyxis Oncology (PYXS – Research Report) on March 18 and set a price target of ...

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent ...

Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...

Brainomix has developed Brainomix 360 Stroke, an AI-powered platform that analyses medical images to support stroke diagnosis and treatment.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...